Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase Ib/IIa Clinical Trial of VG161 Combined With Camrelizumab in the Treatment of Advanced Primary Hepatocellular Carcinoma

NCT06124001 is registered in ClinicalTrials.gov with CNBG-Virogin Biotech (Shanghai) Ltd. as lead sponsor.

NCT NCT06124001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06124001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase Ib/IIa Clinical Trial of VG161 Combined With Camrelizumab in the Treatment of Advanced Primary Hepatocellular Carcinoma
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2023
Completion date
June 30, 2026
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary hepatocellular carcinoma